+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
mRNA Vaccine Raw Materials Market by Material Type (Buffers, Capping Enzymes, Lipids), Delivery System (Exosome Based, Lipid Nanoparticles, Peptide Based), Process Stage, End Use, Application - Global Forecast 2025-2030- Product Image
mRNA Vaccine Raw Materials Market by Material Type (Buffers, Capping Enzymes, Lipids), Delivery System (Exosome Based, Lipid Nanoparticles, Peptide Based), Process Stage, End Use, Application - Global Forecast 2025-2030- Product Image
New

mRNA Vaccine Raw Materials Market by Material Type (Buffers, Capping Enzymes, Lipids), Delivery System (Exosome Based, Lipid Nanoparticles, Peptide Based), Process Stage, End Use, Application - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 192 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6145721
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The global mRNA vaccine raw materials ecosystem serves as the bedrock for accelerated vaccine innovation, underpinning every stage from synthesis to final formulation. As mRNA technology gains unprecedented prominence, the complex network of specialized reagents, lipids, enzymes, and solvents that enable safe and effective delivery becomes critically important. Growing demand for rapid pandemic response has shone a spotlight on supply chain reliability and the necessity of securing high‐quality inputs at scale.

This introduction highlights the essential components and drivers shaping this dynamic market. Advances in lipid nanoparticle design have unlocked new delivery efficiencies, while precision synthesis of nucleotide triphosphates ensures the fidelity of mRNA constructs. Concurrently, regulatory agencies worldwide are evolving quality standards to keep pace with technological breakthroughs. In this context, stakeholders must navigate a multifaceted landscape of materials, processes, and policies to maintain agility and meet burgeoning clinical and commercial needs. By understanding these foundational elements, decision makers can better anticipate challenges and leverage emerging opportunities in the mRNA vaccine raw materials domain.

An In-Depth Exploration of the Transformative Technological and Regulatory Shifts Redefining the mRNA Vaccine Raw Materials Landscape Over Time

The mRNA vaccine raw materials landscape has undergone transformative shifts driven by breakthroughs in lipid science, enzyme engineering, and advanced purification technologies. Over the past several years, the refinement of ionizable lipid formulations and high‐efficiency capping enzymes has elevated delivery performance, enabling vaccines to achieve targeted cellular uptake with minimal adverse reactions. At the same time, innovations in resin design have accelerated purification workflows, reducing process times and improving yield consistency across diverse production scales.

Moreover, evolving regulatory paradigms have facilitated faster authorization pathways, encouraging manufacturers to adopt novel raw material suppliers and alternate sourcing models. This regulatory flexibility, while fostering innovation, also demands stringent quality management systems and robust supply chain transparency. In parallel, heightened emphasis on sustainability has prompted material providers to explore greener solvent alternatives and energy‐efficient synthesis routes. These collective shifts are reshaping the ecosystem, driving both competitive differentiation and collaboration among pharmaceutical, biotech, and specialty chemical players, ultimately redefining how raw materials underpin the next generation of mRNA vaccine platforms.

An Analytical Perspective on the Cumulative Effects of Newly Implemented United States Tariffs on mRNA Vaccine Raw Materials Import and Supply Chains

Recent tariff adjustments implemented by the United States have introduced a new layer of complexity for organizations that rely on international imports of mRNA vaccine raw materials. As a result of these measures, import duties have been recalibrated for key inputs such as specialty lipids, purification resins, and nucleotide precursors. The elevated cost structure has prompted procurement teams to reevaluate supplier contracts, triggering dual strategies focused on cost mitigation and supply chain diversification.

Consequently, some manufacturers have accelerated investments in domestic production capabilities to maintain continuity of supply under fluctuating tariff regimes. Others are forging strategic partnerships with alternative overseas producers in markets with more favorable trade conditions. In parallel, logistics providers have introduced value‐added services aimed at optimizing cross‐border shipments to reduce total landed cost. These adjustments collectively underscore the importance of adaptive sourcing approaches and agile risk management frameworks, ensuring that organizations can sustain R&D and commercial manufacturing timelines without compromising quality or operational resilience.

Insights into key segmentation drivers spanning material types delivery systems process stages and end uses shaping mRNA vaccine raw materials strategy

The market for mRNA vaccine raw materials can be understood through multiple segmentation lenses that reveal distinct demand drivers and value creation pathways. Based on material type, the ecosystem encompasses a broad range of components including buffers such as HEPES, phosphate buffer, and Tris buffer, alongside capping enzymes exemplified by Vaccinia capping enzyme. Lipid inputs span cholesterol, ionizable lipids, PEGylated lipids, and structural lipids, while nucleotide triphosphates cover ATP, CTP, GTP, and UTP. Purification resins include both affinity and ion exchange categories, with salt reagents like potassium chloride and sodium chloride supporting critical formulation stability. Solvents such as ethanol and isopropanol complete this material typology.

Delivery system segmentation highlights the pivotal role of exosome‐based carriers-both engineered and natural-together with lipid nanoparticle variants comprising ionizable and PEGylated lipid particles. Peptide carriers span cell penetrating and fusogenic peptides, and polymeric alternatives include chitosan and PLGA particles. Process stage segmentation clarifies the material requirements at capping, filling and finishing, formulation, purification, and synthesis phases. End‐use segmentation differentiates between human vaccine applications and veterinary programs. Finally, application segmentation distinguishes drives for infectious disease vaccines, including COVID‐19 and influenza formulations, from oncology initiatives focused on hematologic and solid tumor targets. This segmentation framework offers a multidimensional view of how specific material categories and application vectors chart unique growth curves in the mRNA vaccine raw materials domain.

Regional perspectives on how Americas Europe Middle East Africa and Asia Pacific market dynamics influence mRNA vaccine raw materials distribution and adoption

Regional dynamics exert profound influence over the availability, distribution, and adoption of mRNA vaccine raw materials. In the Americas, robust infrastructure and established supply networks support rapid scale-up capabilities, yet emerging trade policies and logistical constraints demand adaptive planning to maintain uninterrupted flows of critical inputs. In contrast, Europe Middle East and Africa exhibit heterogeneous market maturity, with leading biomanufacturing hubs in Western Europe complemented by nascent capacity building in the Gulf and North Africa, where regulatory harmonization and local sourcing initiatives are gaining momentum.

Across the Asia Pacific, a confluence of state-led investment in biopharma infrastructure and competitive cost structures has created a fertile environment for raw material innovation and large-scale production. However, geopolitical shifts and localized quality assurance standards require stakeholders to calibrate regional strategies, ensuring material consistency and compliance. Understanding these regional contours enables organizations to optimize distribution channels, forge strategic partnerships, and anticipate shifts in demand, thereby enhancing resilience and responsiveness in a market where agility is paramount.

Corporate insights into innovation pipelines competitive strengths and partnership strategies among leading mRNA vaccine raw materials suppliers

Leading suppliers in the mRNA vaccine raw materials space are distinguished by their capacity to deliver highly specialized reagents while maintaining rigorous quality standards. Some firms have established integrated lipid manufacturing facilities that leverage proprietary synthesis platforms to produce ionizable and PEGylated lipids at scale. Others have invested heavily in enzymology expertise, expanding their portfolios of capping enzymes and polymerases to meet precise capsid and amplification requirements.

In addition, strategic collaborations between chemical providers and contract development and manufacturing organizations have emerged, ensuring seamless material qualification and regulatory alignment. A select group of market participants have also prioritized geographic expansion, opening new production sites in Asia Pacific and the Americas to mitigate tariff impacts and logistics bottlenecks. Collectively, these company strategies underscore a competitive landscape where innovation pipelines, supply chain resilience, and partnership networks define market leadership and help fulfill the evolving needs of vaccine developers.

Actionable recommendations to empower industry leaders in optimizing procurement manufacturing and collaboration for mRNA vaccine raw materials excellence

Industry leaders must adopt a multifaceted strategy to navigate the complexities of the mRNA vaccine raw materials market and secure a sustainable competitive advantage. First, organizations should diversify their supplier base by qualifying multiple providers of critical inputs such as specialized lipids and nucleotide triphosphates, thereby mitigating concentrated supply risks. Second, investing in scalable in-house synthesis capabilities for high-value reagents can reduce dependency on external markets and buffer against geopolitical uncertainties.

At the same time, fostering collaborative partnerships with academic institutions and technology pioneers can accelerate materials innovation and drive down cycle times for validation. Moreover, engaging proactively with regulatory bodies to align on quality standards and expedite material approvals will ensure smoother market entry and reduce lag times. Finally, enhancing end-to-end supply chain transparency through digital tracking solutions can improve demand forecasting and inventory management, empowering teams to respond swiftly to unforeseen disruptions and maintain uninterrupted production rhythms.

An In-Depth Overview of the Research Methodology Underpinning Comprehensive Analysis of mRNA Vaccine Raw Materials Market Data and Insights

The research underpinning this analysis combines a rigorous blend of primary and secondary methodologies to ensure comprehensive validation of insights. Primary research involved in-depth interviews with material suppliers, logistics providers, and end-use manufacturers, providing firsthand perspectives on emerging trends, operational challenges, and strategic priorities. Secondary research drew upon peer-reviewed publications, patent filings, regulatory guidelines, and publicly disclosed financial reports to construct a robust data foundation.

This data was subjected to triangulation, cross-referencing multiple information streams to enhance accuracy and consistency. Expert panels with subject matter specialists in lipid chemistry, enzymology, and regulatory affairs reviewed draft findings, refining assumptions and clarifying technical nuances. Quality assurance protocols were implemented throughout the process, featuring iterative reviews and validation checkpoints to uphold the integrity of conclusions. This layered approach ensures that the analysis reflects the latest industry developments and delivers actionable intelligence for stakeholders across the mRNA vaccine raw materials value chain.

A Concise Conclusion Synthesizing Key Findings Strategic Implications and Future Considerations for Stakeholders in mRNA Vaccine Raw Materials

This executive summary has synthesized the essential dynamics shaping the mRNA vaccine raw materials market, from material innovation and delivery breakthroughs to tariff recalibrations and regional supply paradigms. Key takeaways underscore the critical importance of segmentation insights that illuminate how distinct material types, delivery systems, process stages, and end-use applications drive differentiated strategies. In parallel, the cumulative impact of updated trade measures compels a shift toward regional manufacturing resilience and strategic partnerships.

As stakeholders chart their next moves, the interplay between technological advancements-such as refined lipid nanoparticle formulations-and evolving regulatory frameworks will define both risk and opportunity. Organizations that harmonize their sourcing strategies with robust quality standards, proactive regulatory engagement, and digital supply chain transparency will be best positioned to accelerate vaccine development and maintain continuity of supply. These insights form the foundation for informed decision-making in an arena where speed, reliability, and innovation are paramount.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Material Type
    • Buffers
      • Hepes
      • Phosphate Buffer
      • Tris Buffer
    • Capping Enzymes
      • Vaccinia Capping Enzyme
    • Lipids
      • Cholesterol
      • Ionizable Lipids
      • Pegylated Lipids
      • Structural Lipids
    • Nucleotide Triphosphates
      • ATP
      • CTP
      • GTP
      • UTP
    • Purification Resins
      • Affinity
      • Ion Exchange
    • Salt Reagents
      • Potassium Chloride
      • Sodium Chloride
    • Solvents
      • Ethanol
      • Isopropanol
  • Delivery System
    • Exosome Based
      • Engineered Exosomes
      • Natural Exosomes
    • Lipid Nanoparticles
      • Ionizable Lipid Particles
      • Pegylated Lipid Particles
    • Peptide Based
      • Cell Penetrating Peptides
      • Fusogenic Peptides
    • Polymeric Nanoparticles
      • Chitosan Particles
      • PLGA Particles
  • Process Stage
    • Capping
    • Filling And Finishing
    • Formulation
    • Purification
    • Synthesis
  • End Use
    • Human Vaccines
    • Veterinary Vaccines
  • Application
    • Infectious Diseases
      • COVID-19 Vaccines
      • Influenza Vaccines
    • Oncology
      • Hematologic Vaccine
      • Solid Tumor Vaccines
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Evonik Industries AG
  • CordenPharma Holding GmbH
  • Avanti Polar Lipids, Inc.
  • Azenta, Inc.
  • Precision NanoSystems Inc.
  • Polyplus-transfection SA
  • Polymun Scientific Immunbiologische Forschung GmbH
  • Acuitas Therapeutics, Inc.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Optimization of enzymatic mRNA cap analog production to enhance vaccine stability
5.2. Integration of recombinant lipid nanoparticle purification techniques to reduce impurities
5.3. Scale-up strategies for in vitro transcription reagents to meet global mRNA vaccine demand
5.4. Development of sustainable raw material sourcing to minimize supply chain disruptions in mRNA production
5.5. Evaluation of novel ionizable lipids for improved endosomal escape in mRNA vaccine delivery systems
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. mRNA Vaccine Raw Materials Market, by Material Type
8.1. Introduction
8.2. Buffers
8.2.1. Hepes
8.2.2. Phosphate Buffer
8.2.3. Tris Buffer
8.3. Capping Enzymes
8.3.1. Vaccinia Capping Enzyme
8.4. Lipids
8.4.1. Cholesterol
8.4.2. Ionizable Lipids
8.4.3. Pegylated Lipids
8.4.4. Structural Lipids
8.5. Nucleotide Triphosphates
8.5.1. ATP
8.5.2. CTP
8.5.3. GTP
8.5.4. UTP
8.6. Purification Resins
8.6.1. Affinity
8.6.2. Ion Exchange
8.7. Salt Reagents
8.7.1. Potassium Chloride
8.7.2. Sodium Chloride
8.8. Solvents
8.8.1. Ethanol
8.8.2. Isopropanol
9. mRNA Vaccine Raw Materials Market, by Delivery System
9.1. Introduction
9.2. Exosome Based
9.2.1. Engineered Exosomes
9.2.2. Natural Exosomes
9.3. Lipid Nanoparticles
9.3.1. Ionizable Lipid Particles
9.3.2. Pegylated Lipid Particles
9.4. Peptide Based
9.4.1. Cell Penetrating Peptides
9.4.2. Fusogenic Peptides
9.5. Polymeric Nanoparticles
9.5.1. Chitosan Particles
9.5.2. PLGA Particles
10. mRNA Vaccine Raw Materials Market, by Process Stage
10.1. Introduction
10.2. Capping
10.3. Filling And Finishing
10.4. Formulation
10.5. Purification
10.6. Synthesis
11. mRNA Vaccine Raw Materials Market, by End Use
11.1. Introduction
11.2. Human Vaccines
11.3. Veterinary Vaccines
12. mRNA Vaccine Raw Materials Market, by Application
12.1. Introduction
12.2. Infectious Diseases
12.2.1. COVID-19 Vaccines
12.2.2. Influenza Vaccines
12.3. Oncology
12.3.1. Hematologic Vaccine
12.3.2. Solid Tumor Vaccines
13. Americas mRNA Vaccine Raw Materials Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa mRNA Vaccine Raw Materials Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific mRNA Vaccine Raw Materials Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. Thermo Fisher Scientific Inc.
16.3.2. Merck KGaA
16.3.3. Evonik Industries AG
16.3.4. CordenPharma Holding GmbH
16.3.5. Avanti Polar Lipids, Inc.
16.3.6. Azenta, Inc.
16.3.7. Precision NanoSystems Inc.
16.3.8. Polyplus-transfection SA
16.3.9. Polymun Scientific Immunbiologische Forschung GmbH
16.3.10. Acuitas Therapeutics, Inc.
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. MRNA VACCINE RAW MATERIALS MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2024 VS 2030 (%)
FIGURE 8. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. MRNA VACCINE RAW MATERIALS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. MRNA VACCINE RAW MATERIALS MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. MRNA VACCINE RAW MATERIALS MARKET: RESEARCHAI
FIGURE 26. MRNA VACCINE RAW MATERIALS MARKET: RESEARCHSTATISTICS
FIGURE 27. MRNA VACCINE RAW MATERIALS MARKET: RESEARCHCONTACTS
FIGURE 28. MRNA VACCINE RAW MATERIALS MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. MRNA VACCINE RAW MATERIALS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY HEPES, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY HEPES, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PHOSPHATE BUFFER, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PHOSPHATE BUFFER, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY TRIS BUFFER, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY TRIS BUFFER, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY VACCINIA CAPPING ENZYME, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY VACCINIA CAPPING ENZYME, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CHOLESTEROL, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CHOLESTEROL, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY IONIZABLE LIPIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY IONIZABLE LIPIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEGYLATED LIPIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEGYLATED LIPIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY STRUCTURAL LIPIDS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY STRUCTURAL LIPIDS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ATP, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ATP, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CTP, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CTP, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY GTP, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY GTP, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY UTP, BY REGION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY UTP, BY REGION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY AFFINITY, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY AFFINITY, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ION EXCHANGE, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ION EXCHANGE, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POTASSIUM CHLORIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POTASSIUM CHLORIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SODIUM CHLORIDE, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SODIUM CHLORIDE, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ETHANOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ETHANOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ISOPROPANOL, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ISOPROPANOL, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ENGINEERED EXOSOMES, BY REGION, 2018-2024 (USD MILLION)
TABLE 80. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ENGINEERED EXOSOMES, BY REGION, 2025-2030 (USD MILLION)
TABLE 81. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NATURAL EXOSOMES, BY REGION, 2018-2024 (USD MILLION)
TABLE 82. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NATURAL EXOSOMES, BY REGION, 2025-2030 (USD MILLION)
TABLE 83. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2018-2024 (USD MILLION)
TABLE 84. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2025-2030 (USD MILLION)
TABLE 85. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 86. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 87. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY IONIZABLE LIPID PARTICLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 88. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY IONIZABLE LIPID PARTICLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 89. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEGYLATED LIPID PARTICLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 90. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEGYLATED LIPID PARTICLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 91. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, 2018-2024 (USD MILLION)
TABLE 92. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, 2025-2030 (USD MILLION)
TABLE 93. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, BY REGION, 2018-2024 (USD MILLION)
TABLE 94. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, BY REGION, 2025-2030 (USD MILLION)
TABLE 95. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CELL PENETRATING PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 96. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CELL PENETRATING PEPTIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 97. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY FUSOGENIC PEPTIDES, BY REGION, 2018-2024 (USD MILLION)
TABLE 98. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY FUSOGENIC PEPTIDES, BY REGION, 2025-2030 (USD MILLION)
TABLE 99. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, 2018-2024 (USD MILLION)
TABLE 100. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, 2025-2030 (USD MILLION)
TABLE 101. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 102. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 103. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CHITOSAN PARTICLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 104. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CHITOSAN PARTICLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 105. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PLGA PARTICLES, BY REGION, 2018-2024 (USD MILLION)
TABLE 106. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PLGA PARTICLES, BY REGION, 2025-2030 (USD MILLION)
TABLE 107. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, 2018-2024 (USD MILLION)
TABLE 108. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, 2025-2030 (USD MILLION)
TABLE 109. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
TABLE 110. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2025-2030 (USD MILLION)
TABLE 111. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING, BY REGION, 2018-2024 (USD MILLION)
TABLE 112. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING, BY REGION, 2025-2030 (USD MILLION)
TABLE 113. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY FILLING AND FINISHING, BY REGION, 2018-2024 (USD MILLION)
TABLE 114. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY FILLING AND FINISHING, BY REGION, 2025-2030 (USD MILLION)
TABLE 115. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY FORMULATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 116. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY FORMULATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 117. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2024 (USD MILLION)
TABLE 118. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION, BY REGION, 2025-2030 (USD MILLION)
TABLE 119. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SYNTHESIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 120. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SYNTHESIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 121. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 122. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 123. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY HUMAN VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 124. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY HUMAN VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 125. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY VETERINARY VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 126. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY VETERINARY VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 127. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 128. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 129. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2024 (USD MILLION)
TABLE 130. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2025-2030 (USD MILLION)
TABLE 131. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COVID-19 VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 132. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COVID-19 VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 133. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFLUENZA VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 134. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFLUENZA VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 135. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 136. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 137. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
TABLE 138. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2030 (USD MILLION)
TABLE 139. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY HEMATOLOGIC VACCINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 140. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY HEMATOLOGIC VACCINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 141. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLID TUMOR VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 142. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLID TUMOR VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 143. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 144. GLOBAL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 145. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
TABLE 146. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
TABLE 147. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2018-2024 (USD MILLION)
TABLE 148. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2025-2030 (USD MILLION)
TABLE 149. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2018-2024 (USD MILLION)
TABLE 150. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2025-2030 (USD MILLION)
TABLE 151. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2018-2024 (USD MILLION)
TABLE 152. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2025-2030 (USD MILLION)
TABLE 153. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2018-2024 (USD MILLION)
TABLE 154. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2025-2030 (USD MILLION)
TABLE 155. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2018-2024 (USD MILLION)
TABLE 156. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2025-2030 (USD MILLION)
TABLE 157. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2018-2024 (USD MILLION)
TABLE 158. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2025-2030 (USD MILLION)
TABLE 159. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2018-2024 (USD MILLION)
TABLE 160. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2025-2030 (USD MILLION)
TABLE 161. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 162. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 163. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2018-2024 (USD MILLION)
TABLE 164. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2025-2030 (USD MILLION)
TABLE 165. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, 2018-2024 (USD MILLION)
TABLE 166. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, 2025-2030 (USD MILLION)
TABLE 167. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, 2018-2024 (USD MILLION)
TABLE 168. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, 2025-2030 (USD MILLION)
TABLE 169. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, 2018-2024 (USD MILLION)
TABLE 170. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, 2025-2030 (USD MILLION)
TABLE 171. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
TABLE 172. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2025-2030 (USD MILLION)
TABLE 173. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 174. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 175. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 176. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 177. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 178. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 179. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 180. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 181. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 182. AMERICAS MRNA VACCINE RAW MATERIALS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 183. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
TABLE 184. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
TABLE 185. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2018-2024 (USD MILLION)
TABLE 186. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2025-2030 (USD MILLION)
TABLE 187. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2018-2024 (USD MILLION)
TABLE 188. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2025-2030 (USD MILLION)
TABLE 189. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2018-2024 (USD MILLION)
TABLE 190. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2025-2030 (USD MILLION)
TABLE 191. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2018-2024 (USD MILLION)
TABLE 192. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2025-2030 (USD MILLION)
TABLE 193. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2018-2024 (USD MILLION)
TABLE 194. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2025-2030 (USD MILLION)
TABLE 195. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2018-2024 (USD MILLION)
TABLE 196. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2025-2030 (USD MILLION)
TABLE 197. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2018-2024 (USD MILLION)
TABLE 198. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2025-2030 (USD MILLION)
TABLE 199. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 200. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 201. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2018-2024 (USD MILLION)
TABLE 202. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2025-2030 (USD MILLION)
TABLE 203. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, 2018-2024 (USD MILLION)
TABLE 204. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, 2025-2030 (USD MILLION)
TABLE 205. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, 2018-2024 (USD MILLION)
TABLE 206. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, 2025-2030 (USD MILLION)
TABLE 207. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, 2018-2024 (USD MILLION)
TABLE 208. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, 2025-2030 (USD MILLION)
TABLE 209. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
TABLE 210. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2025-2030 (USD MILLION)
TABLE 211. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 212. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 213. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 214. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 215. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 216. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 217. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 218. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 219. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 220. UNITED STATES MRNA VACCINE RAW MATERIALS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 221. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
TABLE 222. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
TABLE 223. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2018-2024 (USD MILLION)
TABLE 224. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2025-2030 (USD MILLION)
TABLE 225. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2018-2024 (USD MILLION)
TABLE 226. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2025-2030 (USD MILLION)
TABLE 227. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2018-2024 (USD MILLION)
TABLE 228. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2025-2030 (USD MILLION)
TABLE 229. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2018-2024 (USD MILLION)
TABLE 230. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2025-2030 (USD MILLION)
TABLE 231. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2018-2024 (USD MILLION)
TABLE 232. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2025-2030 (USD MILLION)
TABLE 233. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2018-2024 (USD MILLION)
TABLE 234. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2025-2030 (USD MILLION)
TABLE 235. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2018-2024 (USD MILLION)
TABLE 236. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2025-2030 (USD MILLION)
TABLE 237. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 238. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 239. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2018-2024 (USD MILLION)
TABLE 240. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2025-2030 (USD MILLION)
TABLE 241. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, 2018-2024 (USD MILLION)
TABLE 242. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, 2025-2030 (USD MILLION)
TABLE 243. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, 2018-2024 (USD MILLION)
TABLE 244. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, 2025-2030 (USD MILLION)
TABLE 245. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, 2018-2024 (USD MILLION)
TABLE 246. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, 2025-2030 (USD MILLION)
TABLE 247. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
TABLE 248. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2025-2030 (USD MILLION)
TABLE 249. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 250. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 251. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 252. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 253. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 254. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 255. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 256. CANADA MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 257. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
TABLE 258. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
TABLE 259. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2018-2024 (USD MILLION)
TABLE 260. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2025-2030 (USD MILLION)
TABLE 261. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2018-2024 (USD MILLION)
TABLE 262. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2025-2030 (USD MILLION)
TABLE 263. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2018-2024 (USD MILLION)
TABLE 264. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2025-2030 (USD MILLION)
TABLE 265. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2018-2024 (USD MILLION)
TABLE 266. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2025-2030 (USD MILLION)
TABLE 267. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2018-2024 (USD MILLION)
TABLE 268. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2025-2030 (USD MILLION)
TABLE 269. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2018-2024 (USD MILLION)
TABLE 270. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2025-2030 (USD MILLION)
TABLE 271. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2018-2024 (USD MILLION)
TABLE 272. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2025-2030 (USD MILLION)
TABLE 273. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 274. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 275. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2018-2024 (USD MILLION)
TABLE 276. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2025-2030 (USD MILLION)
TABLE 277. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, 2018-2024 (USD MILLION)
TABLE 278. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, 2025-2030 (USD MILLION)
TABLE 279. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, 2018-2024 (USD MILLION)
TABLE 280. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PEPTIDE BASED, 2025-2030 (USD MILLION)
TABLE 281. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, 2018-2024 (USD MILLION)
TABLE 282. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY POLYMERIC NANOPARTICLES, 2025-2030 (USD MILLION)
TABLE 283. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2018-2024 (USD MILLION)
TABLE 284. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PROCESS STAGE, 2025-2030 (USD MILLION)
TABLE 285. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2018-2024 (USD MILLION)
TABLE 286. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY END USE, 2025-2030 (USD MILLION)
TABLE 287. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 288. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 289. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2024 (USD MILLION)
TABLE 290. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY INFECTIOUS DISEASES, 2025-2030 (USD MILLION)
TABLE 291. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
TABLE 292. MEXICO MRNA VACCINE RAW MATERIALS MARKET SIZE, BY ONCOLOGY, 2025-2030 (USD MILLION)
TABLE 293. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2018-2024 (USD MILLION)
TABLE 294. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY MATERIAL TYPE, 2025-2030 (USD MILLION)
TABLE 295. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2018-2024 (USD MILLION)
TABLE 296. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY BUFFERS, 2025-2030 (USD MILLION)
TABLE 297. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2018-2024 (USD MILLION)
TABLE 298. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY CAPPING ENZYMES, 2025-2030 (USD MILLION)
TABLE 299. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2018-2024 (USD MILLION)
TABLE 300. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPIDS, 2025-2030 (USD MILLION)
TABLE 301. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2018-2024 (USD MILLION)
TABLE 302. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY NUCLEOTIDE TRIPHOSPHATES, 2025-2030 (USD MILLION)
TABLE 303. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2018-2024 (USD MILLION)
TABLE 304. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY PURIFICATION RESINS, 2025-2030 (USD MILLION)
TABLE 305. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2018-2024 (USD MILLION)
TABLE 306. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SALT REAGENTS, 2025-2030 (USD MILLION)
TABLE 307. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2018-2024 (USD MILLION)
TABLE 308. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY SOLVENTS, 2025-2030 (USD MILLION)
TABLE 309. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2018-2024 (USD MILLION)
TABLE 310. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY DELIVERY SYSTEM, 2025-2030 (USD MILLION)
TABLE 311. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2018-2024 (USD MILLION)
TABLE 312. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY EXOSOME BASED, 2025-2030 (USD MILLION)
TABLE 313. BRAZIL MRNA VACCINE RAW MATERIALS MARKET SIZE, BY LIPID NANOPARTICLES, 2018-2024 (USD MILLION)
TABLE 314. BRAZIL MRNA VACCINE RAW MATE

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this mRNA Vaccine Raw Materials market report include:
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Evonik Industries AG
  • CordenPharma Holding GmbH
  • Avanti Polar Lipids, Inc.
  • Azenta, Inc.
  • Precision NanoSystems Inc.
  • Polyplus-transfection SA
  • Polymun Scientific Immunbiologische Forschung GmbH
  • Acuitas Therapeutics, Inc.

Related Topics

Related Reports

mRNA Vaccine Drugs Development Services Market by Service Type, Platform Type, Delivery Technology, Therapeutic Area, End User, Manufacturing Scale - Global Forecast 2025-2030 - Product Image

mRNA Vaccine Drugs Development Services Market by Service Type, Platform Type, Delivery Technology, Therapeutic Area, End User, Manufacturing Scale - Global Forecast 2025-2030

  • Report
  • 187 Pages
  • Global
From
mRNA Vaccines Market by Technology Type, Route of Administration, Manufacturing Process, Vaccine Classification, Application Areas, Distribution Channel - Global Forecast 2025-2030 - Product Image

mRNA Vaccines Market by Technology Type, Route of Administration, Manufacturing Process, Vaccine Classification, Application Areas, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 180 Pages
  • Global
From
mRNA Platform Market by Product Type (Diagnostics, Drug Discovery Reagents, Research Kits), Therapeutic Area (Cardiology, Infectious, Neurologic), End User - Global Forecast 2025-2030 - Product Image

mRNA Platform Market by Product Type (Diagnostics, Drug Discovery Reagents, Research Kits), Therapeutic Area (Cardiology, Infectious, Neurologic), End User - Global Forecast 2025-2030

  • Report
  • 192 Pages
  • Global
From
Nanomaterial-Based Adjuvants Vaccine Market by Vaccine Formulation (Conjugate, DNA, mRNA), Nanomaterial Type (Inorganic Nanoparticles, Lipid Nanoparticles, Polymer Nanoparticles), Application, Route of Administration, End User - Global Forecast 2025-2030 - Product Image

Nanomaterial-Based Adjuvants Vaccine Market by Vaccine Formulation (Conjugate, DNA, mRNA), Nanomaterial Type (Inorganic Nanoparticles, Lipid Nanoparticles, Polymer Nanoparticles), Application, Route of Administration, End User - Global Forecast 2025-2030

  • Report
  • 191 Pages
  • Global
From
Infectious Vaccines Market by Vaccine Type (Conjugate, Inactivated, Live Attenuated), Route Of Administration (Intradermal, Intramuscular, Intranasal), End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Infectious Vaccines Market by Vaccine Type (Conjugate, Inactivated, Live Attenuated), Route Of Administration (Intradermal, Intramuscular, Intranasal), End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 182 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.